An integrated theranostic system for breast cancer

乳腺癌综合治疗诊断系统

• 批准号: 9975111
• 负责人: Elisa E. Konofagou
• 金额: $ 54.98万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-11 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9975111
• 关键词: Ablation; Address; Aftercare; Age; Anesthesia procedures; Animals; Benign; Blood; Breast; Breast Cancer Model; Breast Cancer Patient; Breast Cancer Treatment; Breast conservation; Bypass; Cancer Etiology; Cessation of life; Cicatrix; Clinic; Clinical; Coagulation Process; Detection; Diagnosis; Diagnostic; Disease; Early treatment; Elasticity; Elderly woman; Engineering; Ensure; Female Breast Carcinoma; Focused Ultrasound; Focused Ultrasound Therapy; General Anesthesia; Generations; Histology; Human; Image; In Situ; Interruption; Ions; Lesion; Local Therapy; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Mammary Gland Parenchyma; Mammary Neoplasms; Mastectomy; Mechanics; Methodology; Methods; Modeling; Monitor; Morbidity - disease rate; Motion; Mus; Nonmetastatic; Normal tissue morphology; Operative Surgical Procedures; Outpatients; Patients; Performance; Population; Procedures; Radiation; Recovery; Risk; Role; Safety; Skin; Specimen; Speed; Survival Rate; System; Techniques; Technology; Testing; Therapeutic; Thermal Ablation Therapy; Thermometry; Time; Translations; Ultrasonography; Woman; base; breast imaging; breast surgery; cancer diagnosis; clinical translation; comparative; cost; cost efficient; high risk; image guided; in vivo; malignant breast neoplasm; minimally invasive; mortality risk; preservation; real time monitoring; side effect; standard care; surgical risk; theranostics; tumor; tumor growth; young woman

Breast cancer is the most frequently diagnosed cancer (excluding skin cancer) in women, and is the second leading cause of cancer death among women in the U.S. Currently, one woman in seven will develop breast cancer in her lifetime. Surgical intervention is warranted in most cases. However, as tumors are being detected at increasingly earlier stages, new methods for less invasive and more focal treatments are warranted. In sharp contrast with its premise, the translation of high-intensity focused ultrasound (HIFU) to the clinic has been comparatively anemic due to the unreliable (B-mode-based) or extremely costly and slow (MRI-based) monitoring techniques available. There has thus been an urgent need for a simple, cost- efficient technology that can reliably and efficiently monitor HIFU treatment and thereby ensure its clinical translation. In order to address both needs and maintain the low cost of HIFU while preserving all its advantages, we have developed the radiation-force-based technique of Harmonic Motion Imaging (HMI) that can be used seamlessly with HIFU for simultaneous tumor targeting and generation and monitoring of ablation, namely HMI for Focused Ultrasound (HMIgFUS). In the proposed study, we will integrate the HMIgFUS into a clinical system that will facilitate translation of HMIFU for the focal, thermal treatment of breast tumors. The underlying hypothesis is that HMIgFUS using parallel beamforming will be capable of optimally monitoring HIFU ablation in a clinical setting where speed of application is key. The team assembled encompasses ultrasound, breast imaging, breast surgery, mouse tumor models and histopathological analysis. Our group has demonstrated that motion estimation using parallel beamforming is feasible 1) at extremely high framerates (up to 5000 fps) ensuring highest quality of motion estimation including 2) high precision displacements, 3) coherent compounding for SNR increase, 4) 2D capability as well as 5) real-time implementation. Such a reliable monitoring technique could prove pivotal in rendering an entirely noninvasive treatment accessible to a wide population of breast cancer patients for the first time by propelling it into fast and reliable outpatient procedure for the focal treatment of benign or small, non-metastatic breast cancer, thus minimizing mortality and risk.

乳腺癌是女性最常见的癌症（不包括皮肤癌）， 目前是美国妇女癌症死亡的第二大原因，一名妇女 在她的一生中，将在七个中发展乳腺癌。大多数手术干预是保证的 案例。但是，随着在越来越早的阶段发现肿瘤，新的方法 有必要减少侵入性和更多的焦点治疗。与其前提形成鲜明对比的是 高强度聚焦超声（HIFU）向诊所的翻译已经相对 由于不可靠（基于B模式）或极为昂贵且缓慢（基于MRI）而导致的贫血 可用的监视技术。因此，迫切需要简单，成本 - 有效的技术可以可靠，有效地监视HIFU治疗，从而确保 它的临床翻译。为了满足两者的需求并保持HIFU的低成本 保留其所有优势，我们开发了基于辐射力的技术 可以与HIFU无缝用于同时使用的谐波运动成像（HMI） 肿瘤的靶向，生成和监测消融，即HMI聚焦 超声（Hmigfus）。在拟议的研究中，我们将将Hmigfus整合到临床上 将促进HMIFU转换乳腺肿瘤的局灶性热处理的系统。 潜在的假设是使用平行波束形成的Hmigfus能够 在应用速度是关键的临床环境中，最佳监视HIFU消融。这 团队组装涵盖超声检查，乳房成像，乳房手术，小鼠肿瘤 模型和组织病理学分析。我们的小组证明了运动估计 使用平行波束形成是可行的1）在极高的帧速率下（最高5000 fps） 确保最高的运动估算质量，包括2）高精度位移，3） SNR增加的相干化合物，4）2D功能以及5）实时 执行。这样可靠的监视技术可能会证明 完全无创的治疗可用于广泛的乳腺癌患者 首次将其推向快速可靠的门诊手术，以进行焦点治疗 良性或小型非转移性乳腺癌，从而最大程度地减少死亡率和风险。